

Company Information	6
	,
Chairman's Statement	
Chairman's Statement	ر
	L
	V
Principal risks and uncertainties	1:
Directors' Biographies	Ξ.
Directors' Remuneration Report	:=
Corporate Governance Report	: s
Report of the Directors	i-
Independent Auditor's Report	.2
Consolidated Income Statement	74
Consolidated Statement of Comprehensive Income	/5
Consolidated Statement of Changes in Equity	.4
Company Statement of Changes in Equity	Į.
Consolidated Balance Sheet	e2
Company Balance Sheet	A
Consolidated Cash Flow Statement	=-
Notes to the Consolidated Cash Flow Statement	8.
Company Cash Flow Statement	\$
Notes to the Company Cash Flow Statement	si
Notes to the Financial Statements	لمر

i Li Igrae PENNICTES tru ≳e reer Sign appointed EL (CLS) Diamber igner to (0.01)

=-==

REGISTERED OFFICE: _-: =

> ura bushesahiri

Company of the EMPTY

REGISTERED NUMBER: 04728199 (England and Wales)

__= Communication of the communication of the communic

u I Ceruraje Ner efer

- --_--

Married District

\$1000 A 1000 MBM Brown Committee 8=== 05-8=105

----1-27 LT

PATENT ATTORNEYS: Julian P. Capput A.

> 万个名义。由于 **Variety and legal**

经外 答款

__ = __

> ====-



Tristel plc is a manufacturer of infection prevention and contamination control products. Its lead technology is a proprietary chlorine dioxide formulation. The Company addresses three distinct markets:

- The Human Healthcare Market Hospital infection prevention via the Tristel brand
- The Contamination Control Market Control of contamination in critical environments via the Crystel brand
- The Animal Healthcare Market Veterinary practice infection prevention via the Anistel brand

Chairman's Statement

During 2015 Tristel made very satisfying progress towards the objectives of our medium term financial plan and our goal of becoming a global brand in infection and contamination control. Turnover increased by 14% to £15.3m and our pre-tax margin rose to 17% from 14% last year. Our international activities contributed £5.5m to global turnover, representing 36% compared to 34% in 2014.



Delivering to our shareholders

A key attribute of our business has been, and I believe will continue to be, its ability to turn profit into cash. Post-tax profit of £2.2m during the year translated into cash holdings at 30 June 2015 of £4.0m, up £1.3m from £2.7m at 30 June 2014, after the payment of dividends during the year of £0.75m.



Our Board

I am pleased to welcome David Orr to our Board as a Non-Executive Director. His career spans the British Army, the City and managing businesses in the packaging industry. He brings to our Board very relevant experience of manufacturing in a tough business environment.

Tristel as a public Company: a retrospective view of the first ten years

We joined the AIM market on 5 June 2005. The flotation price was 37 pence per share. Revenue in our first year as a public Company was £3.0m. During the past ten years we have achieved compound annual growth in sales of 18%. Pre-tax profits have increased from £0.1m to £2.55m

Chairman's Statement - continued



We have established a significant geographical footprint and sell through our own direct operations in the United Kingdom, Germany, Switzerland, Austria, Russia, China, Hong Kong and New Zealand and through 36 national distributors. In aggregate our products are currently being supplied to 38 countries.

During the past decade we have returned £5.9m to our shareholders as dividend. Between flotation and 30 June 2015 the Tristel share price has increased by 173%. In comparison, during this period the AIM All Share Index has declined by 22%.

Outlook

The value of this retrospective is not so much to judge the achievements of the past, but more to provide us with an analytical framework to assess what we can achieve over the next decade.



The corollary of having to fight the pace of change in healthcare to gain (albeit slowly) dominance in clinical areas like ENT is that we are equally difficult to dislodge by rival products or a new technology. This characteristic of our business, combined with the fact that over 95% of our revenues are of repeat consumable products that perform a vital function in hospitals, has always encouraged me to view the Tristel business model as very resilient.

As we continue to extend our geographical footprint, and as the enterprises of our distributors (many of which are today almost exclusively focused on the Tristel product range) develop further and expand, it is conceivable that the pace of our growth could accelerate. Furthermore, we have embarked upon our United States regulatory approvals project and we have a more exciting pipeline of new product innovations than I have ever witnessed in our corporate history. For now, however, I am comfortable with our stated growth objectives

Finally, and as I said in my interim statement in February 2015, we have the people, experience of our industry, and physical resources to make further progress this year and into the foreseeable future.

Percent Soe Driving Billstoper (III)

Chief Executive's report

Tristel is a manufacturer and supplier of infection prevention and contamination control products that are based upon its proprietary chlorine dioxide chemistry.

Towards a global brand

With three distinctively branded portfolios – Tristel for human health, Crystel for contamination control, and Anistel for animal health – we are one of only a small number of companies that has an exclusive focus on infection prevention and that has a significant international presence. Our international sales of £5.5m represented 36% of Group turnover in the year, compared to 34% in 2014 and 7% five years ago.

Becoming a global brand in infection prevention is a key strategic objective for Tristel. Via our direct operations and distributors, our products are represented in 38 countries. However, our products have still to tap into such significant geographical markets as the United States and Canada; the great majority of South America; India; much of Central Europe; the African continent with the exception of a very small presence in South Africa; and much of South East Asia.

Continued international expansion is, therefore, going to be a major driving force for our future growth.

Obtaining regulatory approval to sell our products is the initial step in entering any overseas market. The regulatory project is sometimes undertaken in conjunction with a distributor, and sometimes on our own, and if we take the latter approach we determine the route to market whilst the regulatory approval is progressing. We have a regulatory approval programme underway in the United States and we are committed to establish a presence in most countries within the Central and South American region by 2017.

Should confusible to All valid to 701 o 1 😙 Suffra f 2003-9 3/8,000 丹亚基里 2009 (C 610,000 7013-11 953,500 20:1-:2 **美国有能力的** 2012-19 3,403,000 401314 4,691,000 2014 15 ሚያልሲ**ነ**ው ÇALG P 4 (%)

	=-=	- - <u></u>	2013-14	% total	11 1111 11
					1111 1114 111
TURN TENTET	4,857,040	■	NO 79 UCO		- - -
Later rater lates	48.7,0551	716	280,0 00	1.41.	Ar F.Wo
	25.6,000	h-th	217 000	's¶u	7.1%
	5,500,000	100%	4,531,000	lonk	2 I/A


The business model employed in the majority of countries in which we sell products is to use a national distribution partner. During the year we sold through 36 national distributors. It is very rare for a national distributor to start its relationship with Tristel by gaining approval for, and selling, all our Group products and typically adds in products as its business grows. This is a source of future organic growth for the Group that is in addition to revenue growth resulting from the appointment of new distributors in new markets.

During the year the Group had direct operations in the United Kingdom, Germany, Switzerland, Austria, Russia, China, Hong Kong and New Zealand. Within these countries our national sales teams not only serve customers directly but also manage distributors and dealers.

Tristel plc
Strategic Report - continued
For the year ended 30 June 2015

Chief Executive's report - continued

<u> </u>			= =	- =	2013-14	% total	4718614181
							Ingress
			5373 JAC	卢투트			Jahn,
			2,090,000	45%			7 I %
			7 20 F 200	100%	15.1	.52%	3 J#L
		: = =- =		= ===	= ==		= ===
	_						
			_ == ==			===	
		=					
	<u> </u>	=	- <u> </u>				
		=	- <u> </u>			=	
		=	- <u> </u>			=	
		=	- <u> </u>			=	
		=	- <u> </u>		= =	=	
		= - _ -				=	
	A11 (s	= - <u>-</u> -	== == =- =- : == ==== 	1), (1 11 p)	11 mm m humarar	=	
	A11 to 3 tes 3c0	■	/////////////////////////////////////	վ, կեսերի Հրկեր	11 1111 11 hrq 111411 1 1116	=	



Appendig plants in paper to Smith N. A. ጎ.ሮዕክ ዕዕፅ Aude-s ስ የዕዕር A PRODUKUL JOKON 7 $\psi_{i,j}(A(A),D(B))$ 164114 N. Mr. 11,0000 700# **6** ne, Milled Japanese 2000 100 1.704.000 **2010 11** 1.707.000

2012-14 30,948,000 2012-15 19,470,000 2014-15 19,480,000

10,010,083

Juni 11

LAGN INT

In the hospital market we focus today upon two distinct areas of infection prevention: instrument decontamination in the outpatient area, and disinfection of critical surfaces. Sales growth within both of these areas has far exceeded the group-wide CAGR of 18%.

Chief Executive's report - continued

Decontamination of instruments used in the out-patient area

We have moved instrument disinfection revenues away from gastro-enterology to the out-patient areas of the hospital. We have achieved this rapid re-positioning of our product portfolio by innovating with our chlorine dioxide chemistry to create disinfectant products that are ideally suited to the small medical instruments used in ENT; cardiology; ultrasound; urology; GI physiology and ophthalmology.

In these clinical areas there is a constant stream of patients requiring diagnostic and minor therapeutic procedures for which clinicians use small instruments that are relatively simple to decontaminate. We have targeted these niches because they are not addressed by our competitors. Globally, revenues from these products have grown at a CAGR of 46% between 2004-5 and 2014-15.

Instrument distriction have	Fire our cations pro-
En .	Saver E
\$3\$6.5	257 0 00
3037-6	453)90 <u>0</u>
4006.7	667(06)
2069.3	1.175 900
á 308-9	1,138,000
4008-10	2,075,060
#0;5 tq	2,554,900
2001.18	<u> የ</u> የ የ የ ነው።
2012-13	5,021,000
2019-04	2,179,000
2044-05	5,928,500
CASE	45%

Disinfection of critical surfaces in hospitals

Tristel's proprietary chlorine dioxide chemistry has two defining features: first, it kills bacterial spores very quickly; second, it is safe to use. As a consequence, Tristel's surface disinfectants provide the most effective stratagem to control *Clostridium difficile*, one of the most problematic pathogens in hospitals. Globally, revenues of our surface disinfectants have grown at a CAGR of 63% between 2006-7 (when they were first introduced) and 2014-15.

	====	_==-	=
		∧ ===	
		1	10,000
111111111	بالسيباب ا		7 142,02312
1111111 11	դ այնու		a ta axin
111111 1111	9991000		የብ ዚር ው
111111 1 1	m djene		Jacopy (1979)
	1,111 11,111111	Salpines.	1, 1007,000
111111111111	. 2014/00/01	Կակումո	40344,000
1111 1 111		71 - ,000	լ, կրոյրըը
╏╏╏╏ ┇┇╬┇┇┇	1, 111 1,111111	161.000	1.464.003 634

Tristel plc Strategic Report - continuedFor the year ended 30 June 2015

Chief Executive's report - continued

Group Results and Finance

Revenue increased by 14% to £15,334,000 (2014: £13,470,000).

Excluding amortisation of intangibles, share-based payments, interest and results from associates, operating profits increased by 31% to £3,023,000 (2014: £2,300,000). Profit before tax for the year was £2,552,000 (2014: £1,823,000). The resulting basic earnings per share were 5.44 pence (2014: 3.25 pence).

Capital investments in the development of new products, patents, regulatory approvals and computer software resulted in additions to intangible assets of £567,000 (2014: £479,000). Purchases of plant, equipment, improvements to property, fixtures and fittings and motor vehicles totalled £496,000 (2014: £677,000).



Tristel plc
Strategic Report - continued
For the year ended 30 June 2015

Key performance indicators, research and development and going concern

Key performance indicators

Management consider the primary financial key performance indications (KPIs) for each segment of the Group to be revenue and gross margin %. These are both measured and monitored closely. Current period revenue is £15.3m (2014: £13.5m); gross margin for the year is 70% (2014: 70%), see note 2 for detailed revenue and gross profit by segment.

In addition to financial KPIs, the Directors measure and monitor closely various non-financial KPIs, these include:



Research and development

The Group continues to invest in the research and development of new products and application methods for its technology. The products currently being developed are expected to make significant contributions to the future growth of the business. The Board regards investment in this area as a prerequisite for success in the medium to long term.



The Directors compile budget and cash flow forecasts, which are stress tested for potential future influences and events. Funding is sought as necessary, in the most appropriate and cost effective form, to a level which provides sufficient headroom to the Group's cash requirements.


The Directors believe that the Group is well placed to manage its business risks successfully despite the current uncertain economic outlook.

After making enquiries, the Directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the Board has continued to adopt the going concern basis in preparing the annual report and financial statements

Tristel plc	
Strategic Report - continued	
For the year ended 30 June 2015	

Principal risks and uncertainties

The key business risks affecting the group are set out below:



Regulatory and legal approval

The ability to continue to market the Group's products is inextricably linked to the Group's ability to achieve and maintain, in a timely manner, regulatory and legal approval in those regions or markets where the Group has a presence.


The challenges in maintaining worldwide legal and regulatory compliance in respect of financial, environmental, quality and health and safety requirements are significant. In particular within the UK, legislation with regard to bribery and corporate manslaughter pose a risk to the Group and its officers. Senior members of the Board, supported by specialist advisors, take responsibility for maintaining legal compliance. Through a risk management process the implications of new regulations and legislation are assessed and the necessary changes and mitigation are implemented.

External risks

The Group's performance is also subject to external macroeconomic conditions and changes in factors such as inflation or public spending. An economic downturn due to a cutback on the supply of funds to the National Health Service, in particular, could negatively affect the Group's revenues.


Financial risks

The Group's activities expose it to a number of financial risks including credit risk, cash flow risk = = = = = = =




Credit risk on liquid funds is limited because the counterparties are banks with high credit ratings assigned by international credit rating agencies. The credit risk on trade and other receivables is managed by agreeing appropriate payment terms with customers, obtaining credit agency ratings of all potential customers; by requiring wherever possible payment for goods in advance or upon delivery; and by closely monitoring customers balances due, to ensure they do not become overdue. In addition, careful consideration is given to operations in emerging or new markets before the Group enters that market.

Group policy is to maintain a strong capital base so as to enhance investor, creditor and market confidence. Surplus funds are placed on time deposits, with cash balances available for immediate withdrawal if required.



Tristel plc
Strategic Report - continued
For the year ended 30 June 2015



The strategic report which incorporates the Company, Chairman's Statement, Chief Executives Report and Strategic overview, Key performance indicators, Research & development, Going concern and Principal risks and uncertainties, was approved by the Board of Directors, and signed on its behalf by:

antiem Zeec

Tristel plc
Directors' Biographies
For the year ended 30 June 2015

Paul Swinney, Chief Executive (Member of Nomination Committee)

Paul Swinney started his career with Brown, Shipley & Co in 1980. He worked for the European banking operations of Norwest Bank Minneapolis and Maryland National Bank, before joining OSI Finance, a specialist in shipping finance, in 1987. In 1993 he co-founded the business that was to become Tristel plc. He has been Chief Executive and a shareholder since inception.


Elizabeth Dixon, Finance Director

Elizabeth Dixon trained with BDO before moving into industry with the Holiday Property Bond Group, where she developed her career ultimately becoming UK Finance Manager. Having joined Tristel in 2007 as Chief Group Accountant, Elizabeth went on to join the Board of Tristel Solutions Ltd in August 2009 and was appointed as Group Finance Director in June 2010.



Christopher Samler, Non-Executive Chairman at 1.7.14, retired from the board on the 15.10.14 and was struck from the register on this date.

Tristel plc Directors' Remuneration Report For the year ended 30 June 2015




Remuneration report

The Board has applied the principles of good governance relating to Directors' remuneration as described below.




Remuneration policy for Executive Directors

The remuneration policy has been designed to ensure that Executive Directors should receive appropriate incentive and reward given their performance, responsibility and experience. When assessing this, the Remuneration Committee seeks to ensure that the policy aligns the interests of the Executive Directors with those of shareholders.



Remuneration package for Executive Directors

Executive Directors' remuneration packages are considered annually by the Remuneration Committee in line with Company policy, with a view to attracting, retaining and motivating Executive Directors of the calibre necessary to deliver the strategic milestones of the Board. Remuneration packages comprise a number of elements as follows:



Annual performance incentive

The Executive Directors are eligible to receive, at the discretion of the Remuneration Committee, an annual bonus. The Remuneration Committee considers the implementation of bonus awards based upon both corporate and personal performance targets and measures, which align to the long term interests of shareholders. Performance targets are put in a view to clearly linking the motivation of individuals to the value drivers of the business.

Pensions and other benefits

The Group does not operate a Group pension scheme; instead individuals receive contributions to their private pension arrangements.

Directors' Remuneration Report - continued

For the year ended 30 June 2015

Remuneration package for Executive Directors - continued

Other benefits provided are life assurance and private medical insurance. Currently no company cars are provided, but Directors are paid a car allowance in accordance with HMRC guidelines.

Share options

Executive Directors may, at the discretion of the Remuneration Committee, be awarded share options. Where share options are granted the option price will always exceed the closing mid-market value of the Company's ordinary shares on the day prior to grant. No share retention obligations are placed upon Directors.

The performance of Executive Directors is evaluated by the Remuneration Committee on an annual basis with a view to ensuring that there is a sufficiently strong link between performance and reward. The results of performance evaluations are taken into consideration as part of the annual remuneration review.

Remuneration policy for Non-Executive Directors

The remuneration of the Non-Executive Directors is determined by the Board as a whole, based on a review of current practices in other equivalent companies. The Non-Executive Directors do not receive any pension payments towards private arrangements, nor do they participate in any of the bonus schemes.

The Non-Executive Directors each have service agreements that are reviewed annually by the Board. All Board members retire at each Annual General Meeting, and at their own request alongside the recommendation of the Nominations Committee, are put forward for re-election.

Directors' remuneration

The Directors received the following remuneration during the year to 30 June 2015.

Name of director	-38-279		Tarable.	Pare-			==	
) - 11 1			_=		===
				F-16-		= =		
				PS:	347-5-0-			
	= 30	- 1			= ===	E ===		
Sala Ser Tapa	IIAU	MV	Į II		270	57 1	75	[1
ರಿ ಷ್ ರಾ ೧ ೮ ೧	1.49	83	Ìψ	ĺ	264	204	7.0	įι
Plon Edecution								
Chi angher també	<u>!</u> L	- 1	57	12	;L	>3	18	- 1
(Art +-8 (Art 10 15)					_			
Frencisco Scien		100						
Payl Remov	411		132	I	- 11	11	197	
House Green trained	ı	- 1				h	121	
30 40 105								
Aggregate emoluments	324	145	36	6	511	618	43	32

Paul Swinney's service contract contains a provision that in the event of a change in control of the Group, he would receive a bonus payment equivalent to 150% of his then prevailing annual salary.

Elizabeth Dixon's service contract contains a provision that in the event of a change in control of the Group, she would receive a bonus payment equivalent to 75% of her then prevailing annual salary.

Directors' Remuneration Report - continued

For the year ended 30 June 2015

Directors' share options

Aggregate emoluments disclosed above include the amount charged to the income statement in accordance with IFRS 2 in respect of the fair value of options granted or held by the Directors to acquire ordinary shares in the Company. Details of options held by the Directors are as follows:

	_	PELLEP	IMBIBL	14896	7 Ata	Lee see		Carlon of
		jula Anton Aprila	emalley his bloo year	The Mark The Mark The Mark	Pares reside el Muses 272	Fa	<u>-</u>	e-servi
12 3≠121	7 H7 H17	450,500	5.4		24.000	= ==	:_=	
	250.IOU	153,000	12	19 000	ว เปลูกกา	≡ ==	=_ =	111111111111
	gran mini	3%7 000			QWC CON		: = =	
	500,000			- 5		===		i mini hi
Elizabeth Dixon	IIII III	EJOH	- 5	-	# 6. 040	<u>-</u>	18-57-5	1 1111 1111
	14714719197	# 0.4641	- 4		AC Billion		5 4 36 Te	//////////////////////////////////////
	1444841	19 994		100	10,6KM	== ==	- 	11111111
	11.1,111.11	10		7		2.00		111111111111111
	(do, codd)		:: D7	7	11:500	75 D0g	<u></u>	1111111
	47,730	$4 \times 2 \times$	1.0	30 °S		≟	_ = = =	21/21/07
	B.1, 250	48.752		41 ***	7.1	==	≣ - <u>=</u>	74/10/09
	47,159		- 6		7	- <u>-</u>	- =====	12/10/13

Options held by the Directors are subject to vesting arrangements over the life of the options. An initial tranche of options become exercisable immediately. Further tranches become exercisable over periods ranging from 12 months to 36 months from grant, or as detailed in the specific instances above, upon change of control of the Group.

Directors' shareholdings


The interests of the Directors in the shares of the Company at 30 June 2015 and 30 June 2014 were:



The market price of the Company's shares as at 30 June 2015 was 101p. The range during the year was 83.5p to 105.5p (source - London Stock Exchange).

Corporate Governance Report

For the year ended 30 June 2015



Board of Directors

The Company is controlled by the Board of Directors, which comprises two Executives, one of whom is the Chief Executive officer, and three Non-Executive Directors. The role of the Chief Executive officer and Chairman are separate.

All Directors are able to take independent advice to assist them in their duties if necessary.



Directors are subject to election by shareholders at the first opportunity after their appointment. In addition all board members retire at each Annual General Meeting, and at their own request alongside the recommendation of the Nominations Committee, are put forward for re-election.

Board and Committee attendance

The Board and its committees met 9 times during the year; the attendance of the Directors at these meetings is detailed below. On the occasions when a director was unable to attend a meeting, any comments he had arising from the information pack circulated prior to the meeting were provided to the Chairman.

		-=
Chaptopher Same:	2	2
Nas Commen	9	9
Litabeth Outer	9	9
Preferate Stern	9	9
Paul Burden	9	8

Committees of the Board




Corporate Governance Report - continued

For the year ended 30 June 2015

Audit Committee

The Audit Committee comprises certain Non-Executive Directors under the Chairmanship of Paul Barnes. Under its terms of reference it meets at least three times a year and amongst other duties, overviews the monitoring of the Group's internal controls, accounting policies and financial reporting, and provides a forum through which the external auditors report. It meets at least once a year with the external auditors without Executive management present.



The Board has considered its policies with regard to internal controls, as set out in the Turnbull Report, and undertook an assessment of the major areas of the business and methods used to monitor and control them. In addition to financial risk, the review covered operational, commercial, regulatory and health and safety. The risk review is an ongoing process with reviews being undertaken on a regular basis.

The key procedures designed to provide an effective system of internal controls that are operating up to the date of sign-off of this report are set out below.

Control environment

There is an organisational structure with clearly defined lines of responsibility and delegation of accountability and authority.

Risk management

The Group employs Directors and senior personnel with the appropriate knowledge and experience for a business engaged in activities in its field of operations, and undertake regular risk assessments and reviews of its activities.

Financial information

The Group prepares detailed budget and working capital projections, which are approved annually by the Board and are maintained and updated regularly throughout the year. Detailed management accounts and working capital cash flows are prepared on a monthly basis, as is a written commentary giving a comparison to budgets and projections identifying any significant variances.

Corporate Governance Report - continued

For the year ended 30 June 2015

Management of liquid resources

The Board is risk averse when investing any surplus cash funds. The Group's treasury management policy was adopted in July 2005, and is reviewed periodically.

The Board has considered it inappropriate to establish an internal audit function, given the size of the Group. However, this decision will be reviewed as the operations of the Group develop.

The Directors present their report with the financial statements of the Company and the Group for the year ended 30 June 2015.


RESULTS AND DIVIDENDS

There was a profit for the year after taxation amounting to £2.215m (2014: £1.272m).

A final dividend of £0.513m (1.26p per share) was paid during the year in respect of the year ended 30 June 2014. (2013: £0.128m (0.32p per share).

An interim dividend of £0.239m (0.585p per share) was paid during the year in respect of the year ended 30 June 2015 (2014: £0.144m, 0.36p per share); a special dividend of £1.242m (3p per share) was paid on 3 August 2015 also in respect of the year ended 30 June 2015 (2014: £nil); and the Directors recommend a final dividend of 2.135p per share (2014: 1.26p per share). If approved, the total distribution of dividends for the year ended 30 June 2015 will be £2.365m (2014: £0.651m).

A review of the Group's performance for the year ended 30 June 2015 is contained in the Chairman's Statement on pages 3 to 4 and the Chief Executive's Report on pages 5 to 8.




David Orr was appointed as a non Executive Director on the 1 October 2015.

The Group provides Directors and Officers indemnity insurance for the benefit of the Directors of the Group. For the year to 30 June 2015 the policy cost £6,570 (2014: £6,570).

Details of Directors' interests in the share capital of the Company are disclosed in the Directors' Remuneration Report set out on pages 13 to 15.

CORPORATE GOVERNANCE

Tristel plc is committed to maintaining high standards of corporate governance and has applied strong and appropriate policies, given the size of the Group, its current stage of development and the constitution of the Board, to reinforce its commitment to corporate governance and is detailed in the Corporate Governance Report.



RESEARCH AND DEVELOPMENT

Reference to the Group's activities in this field can be found within the Strategic report, on page 9 of these financial statements.

FUTURE DEVELOPMENTS

Reference to this topic can be found within the Strategic report, on page 4 of these financial statements.

FINANCIAL INSTRUMENTS


The instruments that can effect and are therefore monitored by the groups are set out within the strategic report on pages 10 to 11 of these financial statements.

PRINCIPLE RISKS AND UNCERTAINTIES

Reference to this topic can be found within the Strategic report on page 10.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The Directors are responsible for preparing the Stategic Report and Financial Statements in accordance with applicable law and regulations.



The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Group's transactions and disclose with reasonable accuracy at any time the financial position of the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors confirm that:

- so far as each Director is aware there is no relevant audit information of which the Company auditor is unaware; and
- the Directors have taken all steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.


AUDITORS

Grant Thornton UK LLP, have expressed willingness to continue in office. In accordance with section 489 (4) of the Companies Act 2006 a resolution to reappoint Grant Thornton UK LLP will be proposed at the Annual General Meeting



Independent Auditor's Report to the members of Tristel plc

For the year ended 30 June 2015




This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website www.frc.org.uk/auditscopeukprivate



Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements.



موجو محا

	-=	1634 4 Med 30 3 me 2005 1 1000	V _B gri ya gya 80. awr 1 246 51500
in the second se	I	(5.174 (4.549)	Led W (# Ded)
_ 			
		== ==- =	
		E.23	=
	 	: wr. :2 -9 -3	1.115 5 11 F
Profit before tax			=
= <u></u>	•	47	65.
	14	2215	,761 1,758
	III 111	=======================================	E 2

All amounts relate to continuing operations.

Consolidated Statement of Comprehensive Income

For the year ended 30 June 2015

	Year (rând (2) Jean (2015 (*000	ਬਿਛਮੇ ਅਖੋਜ਼ਦੀ 30 . ਸਾਵ 221≜ (1908
Profit for the period	::2:	=
	= ==	
	N	ь
Items that will be reclassified subsequently to profit and I Exchange differences on translation of foreign operations Other comprehensive income for the period	(57)	
Total comprehensive income for the period		
	१७४	(13) 1,242
	_=	_=

Consolidated Statement of Changes in Equity For the year ended 30 June 2015

	18 kej rapatal	VALAN permekan secoure	energy energy			Tes 2014/201 27 804/20 37 72 38 93	Section (C)	150al Digarita
	•	= =	="200	- 14	7	: 388	===	-
=_==	==	- <u>=</u>	===	二 1	=_=		rest	<u> </u>
	1.0		F)	¥1		14729	18	[222]
ion de	2	13	10	33	13	L35	- 3	1 15
= <u>===</u> -	- 5			±	i,	l:		:=
	,	· 두	.+	9	Œ	Œ		Œ
=- ===============================		- 1	10	1	_3	_=_	29	
(Albert selfelelelen fer income (et an annee on trans in an annee opensiver	_	_	_	34	_	34	15	49
Total comprehensive								
гости 10 км ₂ (24 е	402	9,284	478	(93)	1,298 2,167	1,332 12,238	(11) (162)	1,321 12,076
,	402	3,204	470	(33)	2,107	12,230	(102)	12,076
LEAVING BUILDING STATES								
Çiri sende guas	[8]	- 5	130	+1		hril	3	14949
Special Control	1.2			30	- 1	048	1.0	çaş.
Adjustment for change of controlling interest				1	(See	p 3	2	Ų.
Mary NHAB SWTTP-15 (MMS 2	- 1		1	- 1	ļ.	_ &	- 1	В.
	12	-31	- 5	j		136	温	5-3
=	- 33	- 5	18					
==_		10	- 4		- 7		7	
Special processes name Spaces of the special processes of the special processes								
967 ov.	- 9	· · · · · ·	9	61		<u> </u>	7	(57)
			-	(r=\	2.24	8.475		
rate Procesti	414	9,920	478	(57) (147)	2,215 3,493	2,158 14,158	7	2,158 14,165
=						,		,===

	=======================================	===	en de en se	"old equits
	:30	-74	:700	
© Prilis	-518	₽ <u>=</u>	- 3	
"Sission": eStreet				
Deditions		1.0	63	11717
interest	/	ᆁ		145
(1779) (32 0 (資本原金 - ¹⁹ 5)	1.4	1	!s	1. 1
Total transactions with owners	2	133	(257)	(122)
	97	6	<u>-</u>	= -
\$.44 <i>6</i> 34	402	9,284	2,018	11,704
Exercises with pures.				
Dividents cat	- 12	6	(52)	17931
Brain state:	12	3		444
Share better terminals (FSS)	8	17.	35	16
Total transactions with owners	12	636	(717)	(69)
	5		1,435	1,435
				· · · · · · · · · · · · · · · · · · ·
	414	9,920	2,736	13,070

		.7535 	.9;4
le-cromate	===	6,000	20073
France		667	الواح
Marking State	11	5,63L	9 5 5 1
- house, section suggests	11	1347	: 273
States	ii s	EA F	3:
		122	7 304
Less sets		1.7.0	
TERM		1,081	J 1981 1
^T TER ON TO PROPER SE	∎11	3,194	J.690
Transfer	h d	4,044	/ Lu1
		:=	
_		555	
	_		
Capital and response			
Share (april)	7. 3		
Shire premium excount		Mphali	11 11111
Meganeses		I¶ / ₩	474
Förthör and flangte reserve		11871	1.11
³ 60.1 155 以下 155.		' 	4111
	-	14.52	• : ₹
igai dinakan kanena ori pret Misuka kaji kesah	-	14.02	
Rose exch		res	
Sign and the	_	RED .	
ಎಲ್ಎನ್ ಈಗಿ ಗಡ ನೀಡಿಕರು ಕೌರ್ವಕ್ರಮ	İ	5.61	.å : set
and the second s			2 : SE
이 경찰 다이 및 교육이 하는 구에 없다. - 그런 물건들		= ■	 :
_ =	11 11		
la-oregiaine			. 71
 — —	Ш		
randrama era da era ra Demos el);; };		****
Top Soliton	rr	į MS	, at
Top some set in the	-	1045	
		1	

The financial statements were approved and authorised for issue by the Board of Directors on 9 October 2015, and were signed on its ball by:

Solver .

	ŀз	6,308 5332	Augs Front
Review ass.			
rempted state		3,444	3 5 5
In secretaria	111	1,746	1 ~
Calabrica Care	11	3	≦
			<u> </u>
-3 			
	;=	級單	= 12
		\$,540	1,795
		1,054	± -17.
		10,792	16403
Software reserve			
åræs um 1s	ند	424	4. ,
Street person sector		1 42	<u> </u>
ieta nel sen s _i a			<u> </u>
		900	:1,736
Line Seite			
Tes — word se	111	3	<u> </u>
Charles et le	11	10	34
		臣	
ka-sa-ya kasina			
XFX35	<u>- 1</u>	<u> </u>	Fall
		Ph.	
ba schierkolde			

The financial statements were approved and authorised for issue by the Board of Directors on 9 October 2015, and were signed on its behalf by:

Registered number 04728199 (England & Wales)

Tristel plc Consolidated Cash Flow Statement For the year ended 30 June 2015

	⊢ ≘	2035 61005	2.15 2000
	P	<u>: 1,40</u>	<u> </u>
	91		= <u></u> -
	_	24	
			=======================================
ins fore and a message white			
ಗಿಕಿತ್ಸ್ ಆರ್ಥ		11	II
ಿಸ್⇔ ಸರಾಜ್ಞಯ <u>ಜ.ಪ</u>		(00.7)	[470]
Purpose of the first period of prior		(46u)	[677]
F 120000 可能的现在分词显现地形成的现在分词			 .
ecupaniti	-	1	
हेता करो असरे असरकार कुळालाका संस्था			
Ser few ton levely annex			
Sat feet ton level y serves . The Esse		347	-866
-		ह्या द्य	-664 7191
.ನಾನ ಆಚರ			
TERESCO		47	ाञ
ANTE BESC PRESENCE SAME ALLES			ात्र 15
usta esso meres sub Svaranes Di perquisio		€ ## EXE EE	(19) 115 (143) (2) (3)
Para Esso Protessas Protessas Paras Lagia Francy Landes		ा स्था हार	739 115 _333
ANTE BESC PRESENCE TO SERVE SEC MEDITAL MAJOR THEORY ACTIONS THE LOCKES IN DRIVING SEC SEC SOFTWARES.		€ ## EXE EE	(19) 115 (143) (2) (3)
ANTE BESC PRESENCE SALE ANTE SO DEPOSITE DE PROPRIEDAD RE LOCASE IN DEL RECESTO DE PROPRIEDAD LES ESCOLOS DE PRESENCIONES PROPRIEDAD	11	SE SE	(29) 1/5 (1/2) (2) (3) (3)
ART BEEC PRESENT SALEMEN SALEMENT SALEMENT AND ARTESTS RELEASED TO ARTEST AND ARTESTS LET ALL COMPANY AND ARTESTS LET ALL COMPANY AND ARTESTS LET ARTESTS	<u></u>	SE SE	(29) 1/5 (1/2) (2) (3) (3)
AND BEEC PROPERTY AND	II	51 51 33 34 34	(29) 1/5 (1/2) (2) (3) (3)
AND BESC MESSAGE SALESSE SA	<u></u>	5 44 51 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	(29) 1/5 (1/2) (2) (3) (3)

Notes to the Consolidated Cash Flow Statement

For the year ended 30 June 2015

i. RECONCILIATION OF PROFIT BEFORE TAX TO CASH GENERATED FROM OPERATIONS

	2015	/ <u>.</u> 36
	£′000	6,000
Projective (Section 1997)	ШШ	1,11.1
Specification of the transporters.	1811.8	ATL
Relational name of says	117	4114
Fas. 5 for process	(m.)	(m)
State (great opening = 45)		!"
Policy and compare of protection that and equipment	199	(17)
. ಇ ಕ್ರಾಮಾನ್ಯ ಪ್ರಕ್ರಿಯ ಕ್ರಾಮಾನ್ಯ	178	1 1
Fillers total	ų.	Ш
Press name	(44)	()
	4,442	λDa
	2	r in ny
	(994)	11 Haj
	(404)	W1. i.
Cash generated from operations		

ii. CASH AND CASH EQUIVALENTS

The amounts disclosed on the cash flow statement in respect of cash and cash equivalents are in respect of these balance sheet amounts.


Year ended 30 June 2015	30 June 2015 £'000	30 June 2014 £'000
Cash and cash equivalents	- E	
Year ended 30 June 2014	Eq=21 :14	2 _=27 3 - 3 2 -
Cash and cash equivalents	3-5 3-5	

		AJ15	A.14
		£.000	£ 000
	4	=	<u> </u>
		==	-5
Cas fast the metal status			
Notes to the second		\$	· <u>, ==</u>
		3	1
he of set i melagatime		30	₹.
Cast Total form? Which provides			
Name:		[747]	•_=
Description of the second		H00	
Share race		0+0	
reco			
let said est la fingraphy activitée			_
		20	_=
in a series — in the			
	b	2,530	

a. RECONCILIATION OF PROFIT/(LOSS) BEFORE TAX TO CASH GENERATED FROM OPERATIONS

	ACLS	#\$A
	(**************************************	\$1200
	796	c <u>'-</u> 2
ATTENT TORSE	177	.14
³ 점 전: * 1 ** *	(34	. F
	144	7:
	⊭ Ji∂	3 5 e;
*5±5 == ==		
	스크(C)	
Cash generated from operations		

L_I CASH AND CASH EQUIVALENTS



Notes to the Consolidated Financial Statements

For the year ended 30 June 2015

ACCOUNTING POLICIES

Basis of accounting

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (EU).



This resulted in the Group changing its accounting policy for the basis of consolidation and definition of control, but has had no further impact on the 2015 financial statements.

Basis of consolidation

The Group financial statements consolidate those of the Company and all of its subsidiary undertakings drawn up to 30 June 2015. Subsidiaries are entities over which the Group has rights or is exposed to variable returns from its involvement with the investee and has the power to affect those returns by controlling the financial and operating policies so as to obtain benefits from its activities. The Group obtains and exercises control through voting rights.

Unrealised gains on transactions between the Group and its subsidiaries are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Amounts reported in the financial statements of subsidiaries have been adjusted where necessary to ensure consistency with the accounting policies adopted by the Group.



Non-controlling interests, presented as part of equity, represent a proportion of a subsidiary's profit or loss and net assets that is not held by the Group. The Group attributes total comprehensive income or loss of subsidiaries between the assets of the parent and the non-controlling interests based on their respective ownership interests.

There was a change in controlling interest in the period related to the Group's ownership of Tristel Asia and Tristel Medical Equipment Co Ltd, the step acquisition makes both entities wholly owned. There was an immaterial amount of consideration arising upon acquisition. The difference between the non-controlling interest and the fair value of the consideration paid is recognised directly in equity attributable to the parent. Reference to this transaction can also be found on page 26 of these financial statements.

Going concern basis

Management have considered the trading performance of the Group with underlying trends and expectations, this forms the basis of the Group's current forecasts. The forecasts in addition to the resources available to the group leave management to believe that the Group will continue for the foreseeable future for a period of not less than twelve months from date of approval of accounts.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

ACCOUNTING POLICIES - continued

Business combinations completed prior to date of transition to IFRS


The Group has elected not to apply IFRS 3 Business Combinations retrospectively to business combinations prior to 30 June 2005.

Accordingly the classification of the combination (acquisition, or merger) remains unchanged from that used under UK GAAP. Assets and liabilities are recognised at the date of transition if they would be recognised under IFRS, and are measured using their UK GAAP carrying amount immediately post-acquisition as deemed cost under IFRS, unless IFRS requires fair value measurement. Deferred tax is adjusted for the impact of any consequential adjustments after taking advantage of the transitional provisions.

The transitional provisions used for past business combinations apply equally to past acquisitions of interests in associates and joint ventures.

ويوجو المحمية

Some relies the or in the Saul of the factor of the source
E ARCONOMICA (A CONTRACTOR DE COMENTE DE COMENTE DE COMENTE DE LA COMENTE DE LA COMENTA DEL
. ''ನ ಪ್ರಕೃತಿ ಸಿಗಿಸಿಕಿಕೆ ಹೊಟ್ಟಿಯ ಕಿರುವ ಕೊಟ್ಟಿಯ ಪ್ರತಿ ಪ್ರಕ್ರೀಯ ಕಾಡುವ ಪ್ರಕ್ರೀಯ ಹೊಟ್ಟಿಯ ಗಾಡುವ ಸ '''ನ ಸಹರ್ವತ ಬಗತ ಸರೆಯ ಪ್ರಕ್ರೀಯ ಕರ್ನು ಗಡುಗೆ ಬಹುದು ಮಾಡಲಿಗೆ ಸಿಗಿಸಿಕ ಕುಡುವುದು ಗಡುಗಳುವರು ಜನು ''' ಪ್ರಕ್ರೀಯ ಗಳುಗಳ ಕೊಟ್ಟಿನ ಗಡಿಗೆ ಇತ್ತು ಪ್ರಕರಣಗಳು ಪ್ರಕ್ರೀಯ ಪ್ರಕ್ರೀಯ ಪ್ರಕ್ರೀಯ ಗಳುಗಳನ್ನು ಮುಂದು ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ರಿಯ ರಾಜಕರಣ ಕರ್ನು ಅವರ ಸಂಪ್ರದೇಶ ಪ್ರಕ್ರೀಯ ಪ್ರಕ್ರೀಯ ಪ್ರಕ್ರೀಯ ಪ್ರಕ್ರಿಯ ಪ್ರತಿ ಪ್ರಕ್ರಿಯ ಪ್ರತಿ ಪ್ರಕ್ರಿಯ ಪ್ರತಿ ಪ್ರಕ್ರಿಯ ಪ್ರತಿಯ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ಷ ಪ್ರಕ್ರಿಯ ಪ್ರತಿಯ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ಷ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ಷ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ಷ ಪ್ರಕ್ರಿಯ ಪ್ರಕ್ಷ ಪ್ರಕ್ಷ ಪ್ರಕ್ಷ ಪ್ರಕ್ಷ ಪ್ರಕ್ಷ ಪ್ರಕ್ಷ ಪ್ರಕ್ಷಣ



Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

... ACCOUNTING POLICIES - continued




		
	= = == ==	
<u>=_</u>		<u> </u>

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

J. ACCOUNTING POLICIES - continued


Where the Group generates revenue from after sales service and maintenance contracts consideration is initially deferred, included in other liabilities and is recognised in revenue on a straight line basis over the term of the agreement.



Intangible assets

Patents, trademarks, licences and proprietary technology

Patents, trademarks and licences that are acquired by the Group are stated at cost less accumulated amortisation and impairment losses. Amortisation is charged over the useful life of the asset, on a straight line basis of between 7 and 20 years.



Provision is made for any impairment. The amortisation of intangible assets is charged to administrative expenses in the income statement on a straight line basis of between 7 years and 25 years.



Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

ACCOUNTING POLICIES - continued

Software


Software that is acquired from third parties by the Group is stated at cost less accumulated amortisation and impairment losses. Amortisation is charged over the useful life of the asset, deemed to be 7 years based on historical trends of software utilisation.

Property, plant and equipment

Property, plant and equipment are held at cost less accumulated depreciation and impairment losses. Depreciation is provided at the following annual rates in order to write off each asset less the estimated residual value of property, plant and equipment over their estimated useful economic lives as follows:



The residual value and useful economic life of property, plant and equipment are reviewed annually.



Foreign currency translation

The consolidated financial statements are presented in GBP, which is also the functional currency of the parent company.

Foreign currency transactions are translated into the functional currency of the respective Group entity, using the exchange rates prevailing at the dates of the transactions (spot exchange rate). Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items denominated in a foreign currency at year-end exchange rates are recognised in profit or loss.

In the Group's financial statements, all assets, liabilities and transactions of Group entities with a functional currency other than GBP are translated into GBP upon consolidation. The functional currencies of the subsidiary entities in the Group have remained unchanged during the reporting period. Due to the nature of the setup of the German branch as a sales and marketing centre for Tristel Solutions Limited, the functional currency of this branch is considered to be sterling.

On consolidation, assets and liabilities have been translated into GBP at the closing rate at the reporting date. Income and expense items are translated at the average exchange rate. Exchange differences are charged or credited to other comprehensive income and recognised in the foreign currency reserve in equity.

1

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015


ACCOUNTING POLICIES - continued

Inventories

Inventories are valued on a first-in, first-out basis (FIFO) at the lower of cost and net realisable value. Cost includes materials and direct labour. Net realisable value is based on estimated selling price, less further costs expected to be incurred to completion and disposal. Provision is made for obsolete and slow moving and defective items where applicable.

Cash and cash equivalents

Cash and cash equivalents comprise cash held by the Group and short term on demand bank deposits with an original maturity of three months or less. The assets are subject to an insignificant risk of change in value. The carrying amount of these assets approximates to their fair value.



Assets held under finance leases and hire purchase contracts are capitalised in the balance sheet and depreciated over their expected useful economic life. The interest element of leasing payments represents a constant proportion of the capital balance outstanding and is charged to the income statement over the period of the lease.

All other leases are regarded as operating leases and the payments made under them are charged to profit/(loss) on a straight line basis over the lease term. Lease incentives are spread over the term of the lease on a straight line basis.



Non-derivative financial instruments comprise investments in equity and debt securities, trade and other receivables, cash and cash equivalents, loans and borrowings, and trade and other payables. Non-derivative financial instruments are recognised initially at fair value, plus any directly attributable transaction costs. Subsequent to initial recognition non-derivative financial instruments are measured as described below.

A financial liability is an obligation to pay cash or other financial asset, an equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities. Financial liabilities and equity instruments are classified according to the substance of the contracted arrangements entered into. All interest related charges arising from borrowings, and any changes in an instruments fair value that are reported in profit or loss are included within finance costs or finance income.

Trade and other receivables

Trade and other receivables are initially recognised at fair value, plus transaction costs. Subsequently they are measured at amortised cost using the effective interest rate method.


Trade and other payables

Trade and other payables, including loans and other borrowings are initially recognised at fair value, net of direct issue costs. Subsequently they are measured at amortised cost using the effective interest rate method.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

1. ACCOUNTING POLICIES - continued



Taxation

The charge for current tax is based on the results for the year as adjusted for items, which are non-assessable or disallowed. It is calculated according to local tax rules, using tax rates enacted or substantively enacted by the balance sheet date.

Deferred tax is provided using the balance sheet liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. A deferred tax asset is recognised only to the extent that it is probable that future taxable profits will be available against which an asset can be utilised. However, deferred tax is not provided on the initial recognition of goodwill, nor on the initial recognition of an asset or liability unless the related transaction is a business combination or affects tax or accounting profit.

Deferred tax on temporary differences associated with shares in subsidiaries and associates is not provided if reversal of these temporary differences can be controlled by the Group and it is probable that reversal will not occur in the foreseeable future. In addition, tax losses available to be carried forward as well as other income tax credits to the Group are assessed for recognition as deferred tax assets.

Changes in deferred tax assets or liabilities are recognised as a component of tax expense in the income statement, except where they relate to items that are charged or credited directly to equity in which case the related deferred tax is also charged or credited directly to equity.

Share-based payments

In accordance with IFRS 2, the fair value of equity-settled share-based payments to employees is determined at the date of grant and is expensed on a straight-line basis over the vesting period on the Group's estimate of shares or options that will eventually vest. In the case of options granted, the fair value is measured by a Black-Scholes pricing model. Further details are set out in note 23.

Where options are granted over the parent company shares to employees of subsidiary undertakings, the cost of investment in the subsidiary is increased by the fair value of the options granted with a corresponding entry included in equity and assessed for impairment in accordance with IAS 36.

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

Pension costs

For money purchase schemes the amount charged to the income statement in respect of pension costs and other postretirement benefits is the contributions payable in the year. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments in the balance sheet.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

.. ACCOUNTING POLICIES - continued

EU adopted IFRSs not yet applied

As of 30 June 2015, the following Standards and Interpretations are in issue but not yet effective and have not been adopted early by the Group:

The Directors anticipate that the adoption of these standards and interpretations in future periods will have no material effect on the financial statements of the Group.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

2. SEGMENTAL ANALYSIS


Management considers the Group's revenue lines to be split into three operating segments, which span the different Group entities. The operating segments consider the nature of the product sold, the nature of production, the class of customer and the method of distribution. The Group's operating segments are identified from the information which is reported to the chief operating decision maker.

The first segment concerns the manufacture, development and sale of infection control and hygiene products which includes products that incorporate the Company's chlorine dioxide chemistry, and are used primarily for infection control in hospitals ("Human Healthcare"). This segment generated approximately 85% (2014: 85%) of Group revenues.

The second segment, which constitutes 5.6% (2014: 5.6%) of the business activity, relates to manufacture and sale of disinfection and cleaning products, into veterinary and animal welfare sectors ("Animal healthcare"). During prior years all sales for this segment were made to a distributor who supplied the end user.

The third segment addresses the pharmaceutical and personal care product manufacturing industries ("Contamination control") and has generated 9.4% (2014: 9%) of the Group's revenues this year.

The operation is monitored and measured on the basis of the key performance indicators of each segment, these being revenue and gross profit, and strategic decisions are made on the basis of revenue and gross profit generating from each segment.



The Group's revenues from external customers are divided into the following geographical areas:-

	Highel- He aliceaped £ 000	Anstruc Hearthcare (1000	Опантана Эксей 2 99 1	01008 2016 41009	Hattyt Heatthcare 1 300		ট লাক্ষা রত। গ্রেক্ট গ্রহণ	1.09040 7.000 61000
_=	=		=	==	=	==	=	_=
== -		=	=		_		=	=
==-			_=				=	

J SEGMENTAL ANALYSIS – continued

Revenues from external customers in the Group's domicile – "United Kingdom", as well as its other major markets, "Rest of the World" – have been identified on the basis of internal management reporting systems, which are also used for VAT purposes.

Human healthcare revenues were derived from a large number of customers, including £4.081m from a single customer which makes up 31% of this segment's revenue (2014: £3.499m being 30%). Animal healthcare revenues were derived from a number of customers, with the largest customer accountable for £0.309m, which represents 35% of revenue for that segment (2014: £0.209m 27% from a single customer).

During the year 26.6% of the Group's total revenues were earned from a single customer (2014: 26%).

The Group's non-current assets are divided into the following geographical areas and by segment:-

=	2100 2001	7,500 4078		1000	7,98 0.000
	4,584	7.05 5			M, POU
- == 	LCI	146	- Te TETTE	3,030	J.510
				1))	205
Non-current assets	7,645	7,581	_	=	

The Groups current assets and liabilities are shown, where identifiable, by segment, below:-

	Human Healthcare	Animal Healthcare	Contamination Control	Group	18137
2015	£'000	£'000	£'000	£'000	4,0400
Segment assets	3,212	209	598	5,281	9.000
Segment Liabilities	165	10	42	2,464	2 001
5.4	1 004	1,000	4.000	N CACAC	i viv
	4.693	TAV	110	3,450	7,417
	r h m	Ag	18	P, HUU	7.734

EMPLOYEES AND DIRECTORS



A charge of £35,000 (2014: £15,000) to share-based payments in accordance with IFRS 2 arises from transactions accounted for as equity-settled share-based payments. This is included within the wages and salaries figure above. No remuneration is paid through the company.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

! EMPLOYEES AND DIRECTORS – continued

The average monthly number of employees during the year was as follows:

The average monthly number of employees du	iring the year was a	s follows:		
				Parties No marchine
				h mag
Settles latere				
Addisor et				_{_1} I
i i general de medical de la composición del composición de la com			11	
Mannette, en Propiete			III	I I I I
			•••	11
			101	98
			2005	Alte
			6.000	61000
_				
			55	-2 -
			E	三
<u> </u>				
			5-	5
			2-6	7.E-
			eau Newspr	
_= ====================================				- ~
======				
<u> </u>			2	2
Remuneration of the highest paid Director dur	ing the		305	- _
year was:				
			: 34	
Emoluments			=	=
Aggregate contributions to money purchase so	nemes			
				=======================================
Remuneration by director is detailed in the Dir	astars' Damiinarati	Danaut an	- 12 +- 15	
Remaineration by director is detailed in the Dir	ectors Remuneration	on keport on page	S 13 to 15.	
Key management compensation	2013	FC 15	7,714	5118
	Greene	(empare	Sirrop	Company
	8,004	€ 000	411160	£ 200
	_			
	=		==	
_ 				

The key management figures given above includes Directors.

Company

The Company had no employees during the year. Directors of the Company were remunerated through its subsidiary. An immaterial amount of this remuneration is considered to be in relation to Tristel plc the Company.

FINANCE INCOME AND COSTS		
	AUSS	2014
	E 000	6200
- <u>-</u> -		
	I.	Ш
টাৰ ভাৰ		
	12	6
Total mate		
	(9)	(10)
	(9)	(10)
PROFIT BEFORE TAX		
The profit before tax is stated after charging:	лu	-U 4
The profit service tax is stated after charging.	(300	! 00G
		. 50-3
ಿಷ್ಟರ ಗೀರ್ಕರ ಆ ಕಾರ್ಡ್ಗಳಲ್ಲಿ ಜನೆ ಪ್ರಕ್ಷಕಲ್ಲ	5,675	1.8114
Serveral on the section of the secti	397	1/7
Destroy of the Property Sarrey Salary	111	ú.2
Profits (construction of project) is an Biograph and		3
and the figure of the growth and the	Ι'''	5
Raterial contemporary between progressions	I	15.6
its corner anterestivation	11	J53
ಸಿಕೆಡ: ಕಾಣಕೀರ)		40
gasti randi ce		96
Spening awarenin lied a populate		255
 For a second equipment 		78
Persecutive repersion	159	57
A more detailed analysis of auditor's remuneration is provided below:		
	#V/5	434
	E.000	cocc
Audit of these financial statements	18	i 🗖
Audit of financial statements of subsidiaries	à i	14
		1 1
Taxation services (parent and subsidiaries)	=	
Other services		

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

J. ____

The taxation charge represents:

	121)	,000
	01000	0.700
Linette general		
Corxider In	353	348
Adjustment in teste College Projects	[35]	[125]
District Supplement of	[213]	i.
Farsign friends	Liè	10
[™] ¢la cure · · · e i	359	123
Ceffined So		
25gMiles അതുമായ വിശ്യാരത്തു പ്രീട്ടെ ക്ര	=	<u></u>
िराध केलेल कर राज		
York discharge in notine Statement		

Factors affecting the tax charge:

The tax assessed for the year differs from the standard rate of corporation tax in the UK. The difference is explained below:

	,7015 C'305	74(4) 300
Profit on ordinary activities before tax	2,552	1,823
	.54	-20
े न <u>ुन्</u> क्र		
Species of the displaying	I	111
িক কর জীবনারন	11	1
ು ಸರಹಾಗಳ ಕೆಲವು ತಿಳಿಸಿಕೊಂಡಲಿಗೆ ಅವರ ಸರಕ್ಷಣೆ ಅಲ	11111	{I} I
Paragraphic Control of the Control o	I .	
Million of the second of the s	13	<u>_</u>
nant was :	-	-
് മായ്യവർ ആരുത്തുന്നതു ഉത്ത്യം	30	
· Tag Salt rights - Ea	===	

У.

L PARENT COMPANY INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the income statement of the parent company is not presented as part of these financial statements. The parent company's profit for the financial year was £1,435m (2014: £0.477m) which includes a dividend of £0.800m received from its subsidiary company Tristel Solutions Limited.

d.	Amounts recognised as distributions to equity holders in the year:	7015 (************************************	7.988 1.7500
		58	- -
		1,242 884	507
		(800)	

The proposed final dividend is subject to approval by shareholders at the forthcoming Annual General Meeting and has not been included as a liability in the financial statements.

EARNINGS PER SHARE


The calculations of earnings per share are based on the following profits and numbers of shares:

Detained profit for the financial year attails at all and the second second	(7005 (7005	74.54 1700
Retained profit for the financial year attributable to equity holders of the parent	2,215	1,298
	Servies 1900 Memoken	shaire 1900 Number
Weighted average number of ordinary shares for the purpose of basic earnings per share Share options	### .25-	3 3
.a.	_ 	<u>=</u>

The calculation of diluted earnings per share includes no outstanding options of ordinary shares at 30 June 2015 (30 June 2014: nil). All outstanding share options are dilutive at 30 June 2015, but were antidilutive at 30 June 2014.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015



The acquired goodwill in respect of Newmarket Technologies Limited (NTL), formerly Tristel Technologies Limited, has been tested for impairment in accordance with IAS 36.

On 30 April 2010 the activities of NTL were hived over to Tristel Solutions Limited. The relevant revenue lines are now separately identifiable within Human Healthcare and form a single cash-generating unit within the Group's management reporting. The goodwill has been allocated to this cash generating unit (CGU) and forms the basis of this review.

The Group tests annually for impairment, or more frequently if there are indications that goodwill might be impaired.

The recoverable amount of the CGU is determined from value in use calculations. The key assumptions for the value in use calculations are those regarding discount rates, growth rates and expected changes to selling prices and direct costs during the period. Management estimates discount rates using pre tax rates that reflect current market assessments of the time value of money. Growth rates are based upon industry growth forecasts within the CGU, likewise, changes in selling prices and direct costs are based on recent history and expectations of future changes in the market.

The Group prepares cash flow forecasts derived from the most recent financial budgets approved by management. Cash flows beyond a five year period are then calculated into perpetuity using a growth rate of 0%, on the basis that the asset is held for the long term benefit of the Group. This rate does not exceed the average long-term growth rate for the relevant market of the CGU. Cash flow forecasts for each CGU are considered, and where deemed appropriate, adjusted to reflect risks specific to the CGU.

The rate used to discount the forecast cash flows for goodwill is 13%, and assuming a zero growth rate. The net present value of profits expected over the next 5 years exceeds the carrying value of £0.667m, with headroom of £2.184m. A sensitivity analysis has been carried out where growth has been forecast to decline at a rate of 5% year on year, at this level the headroom is £1.788m, as such no impairment has been recorded.



Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

■ INTANGIBLE ASSETS

The Group's approach to reviewing the carrying value of its intangible assets is consistent with the method applied to goodwill held by the Group (set out within note 11, on page 49 of these financial statements).

The rate used to discount the forecast cash flows for all CGU's is 13%, where sensitivity analysis has been carried out, it has been via the removal of growth expectations within a CGU.



Also included within this category are patents and manufacturing rights to the range of products which address the Human healthcare market, and that are related to the Group's propriety technology. These assets are amortised over their expected useful life of between 7 and 25 years. The Human Healthcare market accounts for approximately 85% of group revenues, notwithstanding this, an impairment review has been conducted and the recoverable amount exceeds the carrying value of the asset of £0.956m by £27.008m.

Development - Marketable products & products in development

Included within marketable products is the cost of development of the Stella disinfectant equipment. An impairment review has been carried out which took into account an extrapolated revenue forecast for the next five years. The recoverable amount based upon the value in use at the balance sheet date is £1,753m, this leaves headroom of £1.024m, as such the carrying value of the asset of £729k is supported, and no impairment was recorded.

Also included is the cost of development for a new chemistry delivery device, the carrying value of this is £233K. Revenue from this item is expected to commence in the financial year 2015-16. An impairment review has been carried out looking at revenue forecasts for a five year period. The estimated recoverable amount exceeds the carrying value of the asset by £288k, however as the device is still in development a sensitivity analysis has been carried out adopting a deduction in total revenues of 25%, at this level headroom of £158k remains, as such no impairment is considered necessary.

The balance of this asset category holds a carrying value of £1,058k and relates to a royalty settlement fee and the cost for the ongoing research and development of new and existing products, primarily for the Human Healthcare market. Also included is the cost of development of a range of disinfectants for the contamination control market. All items have been tested for impairment using the discount rate of 13%, at this level the minimal headroom attributable to any of the assets held is £843k, as such no impairment would be required to be recorded.



· These.	ها ماهاد د چین ا	I			
	Patents.	Jenografi	Servings with		
	indeals and	- Ramesole	· Prateir a	Sattlege	
Seni	1 -70-65- 1		letter e :		
<u></u> -	Carrierado Secuendos	= 366	:::		2304
Ist	=, -		= - 		: 344
新长品的	= ≢≅	-0_5 -5 -5	-	-	<u> </u>
Per all Page 15	-	_= <u>=</u> -	:	_	-
	<u>: E.</u>	350	5 =	-	
Delese		<u> </u>		<u>-</u>	
e Kleyn.	■ == <u></u>	-1 ===	드	-	: 3 45
Patenti me		悪	125	Ħ	562
C 62662 82 7200 mg 2 9 05	<u>\$</u>				
SAUTAD	<u> </u>	< H2	HE		
TO BE THE POST OF					
At 30 June 2011	L=	= =	<u>=</u> =		_=
Charge for year					==
48 10 June 2014	=		=		
Floring for year	=				■=
Dinbakir					
At 30 tune 2013					_=
Set apple asset					
k Kleeda	3,514	1,739	233	145	5,631
SECTION.	3,503	2,027	107		5,637
		Palamon para	-		
		ich⊤ce 27060	-764		
			-		
		45 <u>~</u>	=		
ATRIUTOTU			<u> </u>		
ist, lit home litted		445	=_=_=		
n rhumun					
M					
#			-		
Al III IIII II II I Elinini din prin		∃ ∃	₽		
11111111111111111111111111111111111111		===			
' '111111' '11'11 11'11		=			
A 111 111 11 11 11 11 11					
751 TO BUILD 75715			_		

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

PROPERTY, PLANT AND EQUIPMENT

111 11 11 11	harassactive pressr (CD)	Pacified macking or £ 600	idensil Vilje (1800)	Michael vehicles £1000	****** :***
MI MI man /III I	:==	_===	<u>:</u> :	:3	<u> =</u>
Moderno Franco Hughirini	9				_
Artatidadi'r	灵			<u>—</u>	_
HPnJrPmlk		=		_=	
74 H H H H H H H H H H		_		_	
հանգ առանությա					
- 1917 (1917) 		151	Ш	=	=
Minimum Maddinala	92	259	21	=	
At 1811 1811 18 18 18 1	<u> </u>	<u> </u>	<u>-</u>		
Dupentum za 44 waa Mil L	43	==		=	_=
Elligibist polynomial disposing		_	_		
Chángô lớc your	2	_	<u> </u>	=	
		<u> </u>			
At 10 line 2014	=	=	=	_	_=
Խով գուհարը։ - անգանութ		(II)		_	
Directed Model According present		2	929	=	=
g braneggy from garane	=	=	_	=	
At 80 July 2012			_		
let licos-cato					
FS1-1952	712	370	41	224	1,347
KK = 980	764	217	25	271	1,277
_					

Company

No property, plant or equipment is held by the Company.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

__ INVESTMENTS



Investment in associate

The Group holds a 20% voting and equity interest in Tristel Italia srl which is accounted for under the equity method.

	C Braker	
— — —	254	=•
	7715	4.14
	(/900)	£ 300
	104	5
.≥2 ° ±	: 22	≣-
Agraniza naras	36	≨s
Per s	.599.	
್ರೆಗೆ ಬರ್ಚಾದ	攻	= :
Part tempetrum per part	<u> </u>	
	Macenia	
	சேம்மு முறியாள்[ஆ	
	and as secure	
	1,000	
- <u></u>	• - • -	
	7,179	
	28	
	7 154	
	16	
ud se-25	7,179	
-		
·I deligi	_	
Fores, 10-apr		
		
he some case		
NE ACT ME	* ***	
い第 Die 教達		

The total amount recognised in the Company balance sheet in relation to options granted over the parent company shares to employees of subsidiaries during the year amounts to a charge of £35,000 (2014: £15,000).

14. INVESTMENTS - continued

		
_ 	-	
=	.364.	<u> 185-</u>
	_ - 5	<u>=</u>
		
		==-
	- <u> </u>	<u>- Ira : </u>
- 		
		<u></u> _
		 _
	Original Property Control	<u> </u>
		
	CS	₹
		<u> </u>
		134
		<u></u>
	Order -	
	52%	<u> </u>
		 -
	: Delsan	
- ==		36 %

Tristel plc Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

ica	Tab)	7219
	CSC	0,000
Fa to 2	<u> </u>	<u>دونون</u>
rangers Fanangers		⊅ 5
	2,550	:,082




TRADE AND OTHER RECEIVABLES

Large-	1014 2000 Arrigi) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	(V), I 11000 -2⇒8¢Any	u 208 Efoco Compania
**************************************	/,918	7,137	1	
AT INCHES HELD LIGHTING	-		4,642	774
	3	重	45.4	753
?ಕರ+ಗಳಡಿ ನಂ⊯ರುವ ಗರ್ಬಕ	34		à P	15
	<u> </u>	==	===	્યાં.

The Directors consider that there are no irrecoverable amounts from the sale of goods other than those already identified and included within the impairment allowance. This position has been determined by reference to past default experience.

A reconciliation of the movement in the allowance for impairment provisions for trade receivables is as follows:



The credit risk on the Group is primarily attributable to its trade receivables. An allowance for impairment has been made where there was an identifiable loss event which, based on previous experience, was evidence of a reduction in recoverability of the cash flows.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

!L TRADE AND OTHER RECEIVABLES - continued


In the animal healthcare segment, the distribution model means that the debt is allocated amongst multiple customers, thereby reducing the credit risk. In the hospital infection control segment, the credit risk is lessened due to the large number of customers. However, these are predominantly situated within a single market, healthcare.

CASH AND CASH EQUIVALENTS



Cash and cash equivalents comprise cash held by the Group and short-term bank deposits with a maturity of three months or less. The carrying amount of these assets approximates to their fair value.

TRADE AND OTHER PAYABLES



FINANCIAL LIABILITIES – INTEREST BEARING LOANS AND BORROWING

	l-:	N¢	(amp	i kg
Terms and loan repayment schedule	2505	20.4	2716	2014
	ECOC	€ 000	5,000	r1000
			4	
		=	-	
				_
		=		_
	_=	_ _		_=_
		===	==	=
_	==	==	_	
Carrier on the				
eliter ears	-			
	Ş-c	==	Serve.	
	51 5	11.4	35	<u></u>
	Man Tax 1		Mars San .	
	esa School Com Present	511175 391346	esar del 256 Parri - 4515	
	:34	5 5 5		
- 1 	-			
				==
== = -=				
<u> </u>			: "3 CI	
				_
				_
				===

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

FINANCIAL INSTRUMENTS

This note presents information about the Group's exposure to risk, the Group's objectives, policies and processes for measuring and managing risk, and the Group's management of capital. Further quantitative disclosures are included throughout these consolidated financial statements.

The Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework.


The Group's risk management policies are established to identify and analyse the risks faced by the Group, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities. The Group, through its training and management standards and procedures, aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations.

Financial risks

The Group's activities expose it to a number of financial risks including credit risk, cash flow risk and exchange rate risk:


Credit risk

The Group's principal financial assets are bank balances and cash, trade and other receivables. The Group's credit risk is primarily attributable to its trade receivables, which are concentrated in a large number of low value customer accounts. In addition, operations in emerging or new markets may have a higher than average risk of political or economic instability, and may carry increased credit risk. In each case the risk to the Group is the recoverability of the cash flows.



Interest rate risk

The Group is exposed to changes in market interest rates through its bank borrowings, which are subject to variable interest rates, however this is not a material risk to the business.



Liquidity risk

Group policy is to maintain a strong capital base so as to enhance investor, creditor and market confidence. Surplus funds are placed on time deposits, with cash balances available for immediate withdrawal if required.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

The second

The following resigned is that the rest earlier was seen as a second rest. The least of the following is the following in the following in the following is the following in the following in the following is the following in the followin

ng daga kangga kangga magang anggang panggang kanggang kanggang kanggang kanggang kanggang kanggang kanggang k Kanggang kanggangkan

- 1500-17-12-19 ರವರ್ಷ-ಮಾರ್ಚರ್ಚಿಕ್ಕಾಗಿಯ ಮಾಡಿಕೆ ಕೆಟ್ಟ್ ಕ್ರಾಡಿಕ್ಕಾಗಿ ಕೆಟ್ಟ್ ಪಡೆದಿಗೆ ಕೆಟ್ಟ್ ಪಡೆದಿಗೆ ಕೆಟ್ಟ್ ಪಡೆದಿಗೆ ಪೂರ್ತಕ್ಕಾಗಿ ಕೇರ್ಟ್ ಪಡೆದಿಗೆ

ಿ ಆರಾ≢ಕಾಗಿ ನಡ್ಡಾಗಿ ನಡ್ಡಿಯ ಸಹಾಹಾದ ಮುಂಡಿ ಕಾಗುವುದಾಗಿ ಬ್ಯಾಪಾಕಕ್ಕೆ ಕರ್ನಡೆ ಮಿಂದಿಗೆ ಸಂಕರ್ಣೆಯ ಮುಂಡಿ ಮಿಂದಿಗೆ ಸಂಕರ್ಣಿಯ ಪ್ರಮುಖ ಕರ್ನಾಪಕ್ಕೆ ಮುಂದಿನ ಮುಂಡಿಯ ಮ

	Geog		Servane	
	273		250.3	45.44
	1,200	1.600	F700	L-000
 -	[A,588	12.2%	24112	23,334
	± Q45	2,544	4.042	35K
E 3	18,210	14,740	16,112	14,234
Kar. T	-55	121.6	==1	= ==
किल इ		80		141
	14,165	12,126	13,070	11,704

====

			===
-84	1-==	5040	_≡
2,908	2,410	4,996	4,165
6,953	5,074	8,038	6,695

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

			6 months	PIQIA	Mark Irrae
	\$requet	22.8 1 7.95	SP 하다	mortim	12 months
	(1000)	# 100E	E/9 00	Г409	£7940
teres isomo					
	4	4	4	-	•
80.01 :30 .4					
೩೯೯-೧೯೮೯ ಈ ಗಿರ್ಗಾಟ					
Transit of section	17	17	17	-	-

The carrying amounts of the Group's financial assets and liabilities may also be categorised as follows:

	Strate		Exercise se	
	3605	7-12	2233	403F
	5400	£ 300	STR06	4.900
			100	
	4,545	A,1444.	F-1	1.0
Training selection	2,900	2 =10	-	- _=
	6,953	5,074	4,996	4,165
All of the above relate to the IAS 39 category 'loar	ns and receivables'.			
to the salita				
		47		
), MB	7,516	N	14
	1,783	2,252	4	17
		10		

All of the above relate to the IAS 39 category 'other financial liabilities'.

Liquidity needs are managed by regular review of the timing of expected receivables and the maintenance of cash on deposit.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

FINANCIAL INSTRUMENTS – continued

Interest rate risk

The Group is exposed to changes in market interest rates through its bank borrowings, which are subject to variable interest rates, however this is not a material risk to the business.

Currency risk

The Group has a limited element of currency risk as it buys certain chemicals, parts and equipment from overseas manufacturers and sells finished products into overseas markets. However, foreign currency risk is not significant.



___ LEASING AGREEMENTS

70% E co o	4011 \$1000
111 #24	,L U41 -++4 Lb
IIMI	h, illa s

Leases comprise of non-cancellable operating leases in relation to property and manufacturing equipment.



22. TAXATION

CURRENT TAX	\$1000		Santanoj		
	216.3	######################################	2 1 5.5	4414	
	3700	£ 000		1,000	
Corporation Tax at 30 June	247	213	117	134	
DEFERRED TAX	=	St.s	Dec.		
	art.i	4-35	35.5	J.384	
	FREE	0.000	₹ 10 0	t 200	
Balance at 1 July	(1221	11.7	•	Ш	
Credited/(charged) to Income Statement for the year	21	(4 76)	(28)	(4)	
Safgrey of 40 Ame	(99)	(121)	(9)	6	
Viade up of					
Deferred the analysis	=	_			
Çeferrez Sur Inibi Des	=	=	_		
Balancy at 16 Ame	_				
	les a sec	LAMP	2-rbush	CHARLANY	
	No. 6 Sec	temporary differences	1 geal	Yaligi (a.e. Amelani	
1900	ਪਤਰ ਾ	#1000	1.020	71999	
	-	(167)	307	10	
		_			
		1,	-54	įŁI	
Earth 18 Lat III		(121)	(121)	6	
िराच्या प्रस् टा । १८७६ १९००	_	22	22	(15)	
		(99)	(99)	(9)	
		(3.2)			
Other temporary differences include tax relief on rese	arch and develop	ment spend.			
Net deferred tax (liability)/asset			Sabut Eliza	<u> </u>	
			Ç Lat.		
				≣	
Green La			=		
			_ =	====	
Balance at 30 June 2014			(121)	6	

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

22. TAXATION - continued

The Group deferred tax asset at 30 June 2015 has been recognised at 20% (2014: 20%) as it is expected that this will be the rate applicable on reversal of the temporary differences.

23. CALLED UP SHARE CAPITAL



1,157,500 ordinary shares of 1 pence each, related to the exercise of 1,157,500 share options were issued during the year (2014: 250,000), for a total consideration of £648,000, being £12,000 equity and £636,000 share premium. The weighted average exercise price was 53.86 pence.

Share-based payments

The Group maintains two share-based payment schemes, a Senior Management Scheme and a General Employee Scheme.



23. CALLED UP SHARE CAPITAL - continued

	Q 111 1 00 111-21-2 0 105-2 111 10-7-3-1-1-1	samuraal menungan n oo bensel	e formal Ambara'any E'seses'an	/Januariana placepea odno alea Di Paris D/	 		
	Дадын по 14-фер (М	gy gleenin An his sain	817 WI. FII. . WJ W	n Maria	1111		1
dama dalah dalah dalah						11 1 111	
nd grann	# 15 p	# 5] 17/45	45 n 11 m	S Apr A 1771	1.1		
e'nderrole Tiponomian	ALIMA Mayarin	Lee pears	in in the second	ili pana	III	11	
լ իրդդասը ըպատրվ	·		-	•		11	111 1
¥4 11. 1. 1 4 1 4.	ያ / Th	a 7 %	7.74	/ 'nl=	I	'	
allow High Hiddle and a contri	a sime	4.44	1'7	•		1 11	
n mar medicere diktoren 196 glavor	m մ հ7 բ	w mit/m	u nam.	HAMBA			
Militaring Brahm managarah managarah	sa Sp	on Jul	ւմ քեր	N I Alem	1 1	1 1	1 1
	i eşi bəri pəşiriy		er nemn. Benlipele k Ennihelle	ււսուդիապիագր			
g/genitions	₽ 0m	11111111	ini maha sia	150 5002 113			
Visit of behavior	9,000,000	[1 m 1]	0 0 My+ 10	114 MA 1-11	111	1 11	
26a - 1ya — yi 4ata Çilgiləri	516	11 111	iai V⊑	MNI SIF			
yaa ee ee g	J.Oc.	1 111	PA	for		1	
Outers Fe English Edition (F	1) - L	111 1111 1111	111 87 61 7	177 8 8 8 9 8	1		
ye r	490	і н II	17.	1"1	I		
Phyllogi acaremani spe	E 1%	ո և հո	leler	4,594			
មិនការសាសមានកិច្ចិកកកើ កំណុ	y Namay	2.00	91.519.611	0.0426		1	11 11
Fancy ver primer pa diam ef (da≐)	ti ba	us ™a +s å a	66.54	⊫I F IIi	1 1	1.1	I
		111 111 111 ₁ 11 111		epera Andreas Andre			
	- <u>25</u> -	1 1 H + 11		Owner 11			
VIII YY Talla Yalal I Tali		11 101 11		elle deel Mal		1 11	ППП
alamat para 11 ad 11 ad 11 ad prama	IIII	Щ	ĺ	a minar		П	
ուտուհար		ı	· ·	•			
ւզուս ահո	III	111 11 11		1		III	
r i por com commune Virini		111		Ц			
MISE HERY Journal Construct Codd (*)		II II		H II	I		
tale autor at mond			11 1111 1				
dan 11811 1111 1111 11 11	1111.11	11111	1 1 1	11 (11)	I	I I	11 1111
'	1 1	1 11	1 1	' ılıl ı	1 1		1 1

CALLED UP SHARE CAPITAL – continued

		i interior d'exployerie Transce		- 1 1 1 1 1 1 1 1	մ իրասանոն գուսայնն բաջար ԱՀ Վարգույայ		
1111 111111	HT M.W. Lil	81 Alex LL	1 11	alid M	1146414	111 11	111
iinna ial Indii! Hlindi i	11*********	113 (432) 13		Hereb	33 Oct 14	11 11	111
taman pamanadan alaman	1111	¶lu	111 111	alden i	I _{1-ր} .	1	
\".# . " .	IIIYI	ትስ መ	1111	بسيا	,11,	I	
111111111111111111111111111111111111111			П	(Maggitte	III poort	1111 11	1
rupurrum rumunum Pumu		1,1		· m	J.Y.	III	1
aliandra Tuna dara adamik Tarana atam	n lin	11 11 11	11	II VV	nA v	II I	
	ппп	иш ј	11 111 1	redsu	6 00u	1	
! '!! '\ \ \	Li	\ _{1 II}	I	7 4 j	hing.	II	

	 ::-::
Creat Car s	. · • · ·
: 	
==	2 ↔ ⊢ ≒
Pare refer	
그 같은데	- -
a : polir-	_ =1
Color et	
 :	-
	1.55
"ar size ar som	
·	: 75mg
Externos	
Same Tight	=

වනු අතුල්දේ සහරජය සම්බන්ගයක් අත සහ සහ සිට විද්යතුම්මේ මියවීම අත මෙන්න්ට මිරිම් සාකාර සා විද්යතු විසා සාක්ර මහර දරුණෙන් හැනවැන්නේ යා ලියන්මේ මෙයි වෙන සම්බන්ග සම්බන්ධ විදි අත සාද සාක්ර මේ




Fair values have been determined using the Black-Scholes model.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

CALLED UP SHARE CAPITAL – continued

A reconciliation of option movements over the year to 30 June 2015 is shown below:-



The total charge at 30 June 2015 relating to employee share-based payment plans, in accordance with IFRS 2, was £35,000 (2014: £15,000) all of which related to equity-settled share-based payment transactions.

The range of exercise prices for options outstanding at the end of the period is 52.75p and 79p. The weighted average of the remaining contractual life of options at the end of the period is seven years.

RELATED PARTY DISCLOSURES

Transactions between the Group and Bruce Green

Under the terms of a technology licence agreement between the Group and Bruce Green, a shareholder in the parent company Tristel plc, royalties and commissions related to the Groups patented technology of £194,000 (2014: £164,000) were payable during the year to Bruce Green Limited, a company owned by Mr Green. At 30 June 2015 the Group owed Bruce Green Limited £42,000 (2014: £33,000).

Transactions between the Group and Tom Allsworth

Under the terms of supply agreements between the Company and Medichem International (Manufacturing) Ltd, a private company incorporated in England and Wales, in which Mr Tom Allsworth, a shareholder in the company is a director and shareholder, monies totalling £148,000 (2014: £114,000) were payable. At 30 June 2014 the Group owed Medichem (International) Manufacturing Ltd £28,000 (2014: £23,000) and was owed £1,000 (2014: £1,000).

Transactions between the Group and associate companies

During the year the group charged its associate company Tristel Italia srl £48,000 (2014: £48,000) in respect of finished goods and was owed £40,000.

Notes to the Consolidated Financial Statements - continued

For the year ended 30 June 2015

RELATED PARTY DISCLOSURES - continued

Transactions with Directors

Dividends were paid to Directors as follows:

	조보에 지난	rii iniib " Arir
	É	L
Depths may	III,µ4≤	6.655
Suggest Degr	21)	40%
Professor Sules	104.035	74,640
iau Bethe	11,104	4,164

During the year Elizabeth Dixon, a director of the Company, was granted options over 10,000 of the company's 1p ordinary shares at a price of 79p.

Details of Directors' and key management compensation are disclosed in note 3.

Chief Executive's report - continued

Group Results and Finance

Revenue increased by 14% to £15,334,000 (2014: £13,470,000).


Excluding amortisation of intangibles, share-based payments, interest and results from associates, operating profits increased by 31% to £3,023,000 (2014: £2,300,000). Profit before tax for the year was £2,552,000 (2014: £1,823,000). The resulting basic earnings per share were 5.44 pence (2014: 3.25 pence).

Capital investments in the development of new products, patents, regulatory approvals and computer software resulted in additions to intangible assets of £567,000 (2014: £479,000). Purchases of plant, equipment, improvements to property, fixtures and fittings and motor vehicles totalled £496,000 (2014: £677,000).

The level of profit during the year has resulted in cash balances increasing to £4,045,000 as at 30 June 2015 from £2,664,000 at 10 June 2014.

ine h-elic

Tristel plc Strategic Report - continuedFor the year ended 30 June 2015



The strategic report which incorporates the Company, Chairman's Statement, Chief Executives Report and Strategic overview, Key performance indicators, Research & development, Going concern and Principal risks and uncertainties, was approved by the Board of Directors, and signed on its behalf by:

RESIDENCE TO THE TOTAL OF THE T

	- -	7015 2014 F1005 £1000
from: ament assets		
Office with		3 ,446 1,545
್ರಾರ್ಣ್ 	11	1,746 1,500
District o	11 11	
		<u> </u>
	! 5	課課 ● 第二
		1442 2530
		E 164 5 71
		\$1.266
Salty and market		
9an.2516	23	F0.4 572
ಆರಂಭಾಗಕಾಗ ಸರ್ವಾರ		3500 1054
erang somm		27 集 第2
		475
ing spile		
	j ∎	- 1 €
ಬಿಕ್ಕ ಕ ಚ	H	
to-sars ladge		<u> </u>
identis	\mathcal{L}	
're-ioliae		296
adeira rise et		235 _ 2

The financial statements were approved and authorised for issue by the Board of Directors on 9 October 2015, and were signed on its behalf by:



Registered number 04728199 (England & Wales)

The notes form part of these financial statements

		2011	8,84
New artest access	- =	E COS	9 200
Empli		B bJ	587
	11	5.631	9 5 3 7
ಿಗಳು ಕರ್ಮನಾಗಕಾ	11	t.H1	3 427
ेर ाहास: 'अ	11	e t.	63
		2,70	7,554
Later Base			
re 7-5		2,000	J DH1
ಿ ಕಾರ್ಚಿಯ ಪ್ರಕ್ಷಣದ ಪ್ರಕ್ಷಣೆ	111	7.174	2.696
		4,040	2,664
Capital and respons			
Share carried	i:		
51219 Stemam ucocant		11/11/4/11	11 11111
Simple exists		П'П	Ч. Ш
Foreign micharge several		\ h /h d \	1444
Returned namings		1,#"11	", ¶ '
:n9ಪಕ್ಕಿಸುವ ಪ್ರಕರ್ಮಕ್ಕೆ ಕಾರಣ		2)13	<u> </u>
Parameter North			\$2°
TEL OCUPE		306	= = = = = = = = = = = = = = = = = = = =
Dimentionities			
Takini dingalah s		349	/ to el
1, despitate de la company	1.1	-	4;
具 特定的基础	ılıl		r.i
			-
la-ore inite			
gasteration to the di	μŲ		<u> </u>
(1997)	77	€'	224
		UNI	163
THE SHOW IN COMPANY		4 ¹ ,014	be:_

The financial statements were approved and authorised for issue by the Board of Directors on 9 October 2015, and were signed on its dehalf by:

Street Street

The notes form part of these financial statements

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The Directors are responsible for preparing the Stategic Report and Financial Statements in accordance with applicable law and regulations.



The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Group's transactions and disclose with reasonable accuracy at any time the financial position of the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors confirm that:

- so far as each Director is aware there is no relevant audit information of which the Company auditor is unaware; and
- the Directors have taken all steps that they ought to have taken as Directors in order to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Directors are responsible for the maintenance and integrity of the corporate and financial information included on the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

AUDITORS

Grant Thornton UK LLP, have expressed willingness to continue in office. In accordance with section 489 (4) of the Companies Act 2006 a resolution to reappoint Grant Thornton UK LLP will be proposed at the Annual General Meeting

